WCM Investment Management LLC trimmed its holdings in shares of Bruker Co. (NASDAQ:BRKR) by 29.2% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 29,900 shares of the medical research company’s stock after selling 12,354 shares during the quarter. WCM Investment Management LLC’s holdings in Bruker were worth $1,493,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Bruker by 8.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,566 shares of the medical research company’s stock valued at $328,000 after buying an additional 492 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Bruker by 7.3% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 7,285 shares of the medical research company’s stock valued at $280,000 after purchasing an additional 494 shares during the last quarter. Strs Ohio grew its holdings in Bruker by 5.3% during the 1st quarter. Strs Ohio now owns 10,685 shares of the medical research company’s stock valued at $410,000 after purchasing an additional 537 shares during the last quarter. GWM Advisors LLC grew its holdings in Bruker by 2.0% during the 2nd quarter. GWM Advisors LLC now owns 45,601 shares of the medical research company’s stock valued at $2,278,000 after purchasing an additional 885 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC bought a new position in Bruker during the 1st quarter valued at about $35,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.
BRKR stock traded down $0.59 during mid-day trading on Friday, reaching $41.67. The company had a trading volume of 19,447 shares, compared to its average volume of 1,194,283. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.19 and a quick ratio of 1.27. The company has a market capitalization of $6.51 billion, a PE ratio of 29.76, a price-to-earnings-growth ratio of 2.09 and a beta of 1.30. The firm has a 50 day moving average of $45.86 and a 200 day moving average of $41.97. Bruker Co. has a 12 month low of $26.10 and a 12 month high of $51.41.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 20th. Shareholders of record on Tuesday, September 3rd will be paid a $0.04 dividend. The ex-dividend date of this dividend is Friday, August 30th. This represents a $0.16 dividend on an annualized basis and a yield of 0.38%. Bruker’s dividend payout ratio is currently 11.43%.
BRKR has been the topic of several analyst reports. UBS Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $43.00 price target on the stock in a report on Friday, May 3rd. Svb Leerink upgraded shares of Bruker from a “market perform” rating to an “outperform” rating and upped their price target for the company from $40.00 to $53.00 in a report on Friday, May 3rd. Needham & Company LLC set a $57.00 price target on shares of Bruker and gave the company a “strong-buy” rating in a report on Monday, June 24th. Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and upped their price target for the company from $32.00 to $48.00 in a report on Monday, July 15th. Finally, Barclays reiterated a “hold” rating and set a $44.00 price target on shares of Bruker in a report on Monday, June 24th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $48.18.
In other Bruker news, CEO Frank H. Laukien sold 400,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $41.48, for a total value of $16,592,000.00. Following the transaction, the chief executive officer now directly owns 37,991,030 shares in the company, valued at approximately $1,575,867,924.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 26.50% of the stock is owned by corporate insiders.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
See Also: What is meant by holder of record?
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.